CF-G5 A volume of 5cc of granules based on the patented highly cross-linked carbohydrate graft that has been cleared through the FDA 510(k) process (K170165). The fetus develops tissues using a carbohydrate structure through glycosylation. This process continues in adulthood where leukocytes use the L-selectin on their surface to attach to damaged blood vessels which are coated with carbohydrate molecules. This Interaction between leukocytes and endothelium that is mediated by carbohydrate-binding proteins (selectins) is the critical first step in the scaffold formation and healing cascade process. Testing has confirmed that CellFuse is nontoxic, biocompatible and non-immunogenetic and can support cell growth over several weeks and binds stem cells efficiently. The graft itself has exceptional handling and hydration characteristics due to it’s cohesive structure making it both suture-able and moldable. The most efficient biologic solutions incorporate multiple capabilities into a single system. Combining the capability of other Cervos products to aspirate marrow, harvest bone dowels, and access damaged bones allows a clinician to bioengineer solutions on the field. Combining marrow aspirate with autogenous bone and a graft extender allows clinicians to fill boney defects using the patient’s own cells as the engine for bone healing. The combination of all three provide cells, signals and a scaffold; the building blocks for repairing bone.